Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Seeking Alpha5d
SLXNW Silexion Therapeutics Corp Wt Exp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...
Morningstar6d
Silexion Therapeutics Corp SLXN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing5d
Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...
Business Insider2d
Silexion Therapeutics Corporation Registered Shs
P/E ratio (year end quote, basic EPS) 253.37 259.61 - - P/E ratio (year end quote, diluted EPS) 253.37 259.61 - - Silexion Therapeutics Dividend Calendar Silexion Therapeutics Calendar Indices ...
Yahoo Finance5d
Silexion Therapeutics Corp (SLXN)
After hours: 7:59:51 p.m. EST Loading Chart for SLXN ...
manilatimes11h
Jushi Holdings Inc. Announces Opening of Relocated Dispensary in Linwood, Pennsylvania through its Subsidiary, Franklin Bioscience - SE LLC
Jushi Holdings Inc. ("Jushi” or the "Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis ...